➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
Mallinckrodt
Merck
Harvard Business School

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Tazemetostat hydrobromide - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for tazemetostat hydrobromide and what is the scope of patent protection?

Tazemetostat hydrobromide is the generic ingredient in one branded drug marketed by Epizyme Inc and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tazemetostat hydrobromide has two hundred and sixty-nine patent family members in thirty-eight countries.

Summary for tazemetostat hydrobromide
International Patents:269
US Patents:20
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 5
Patent Applications: 6
DailyMed Link:tazemetostat hydrobromide at DailyMed

US Patents and Regulatory Information for tazemetostat hydrobromide

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
AstraZeneca
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
 NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group